Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03918629 · ClinicalTrials.gov registry record · Phase 3
Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,994
- Enrollment target
NCT03918629 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,994 participants.
The verdict
NCT03918629, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,994 participants
- Enrollment target
Study Summary
This study will investigate a Clostridium difficile vaccine in adults 50 years of age and older. In half the adults, all 3 doses given are the Clostridium difficile vaccine, and in half the adults, 2 of the 3 doses are the Clostridium difficile vaccine with the other dose containing no active ingredients. The study will look at the subjects' immune response to the vaccine and assess the safety and tolerability of a 2-dose regimen of Clostridium difficile vaccine compared to a 3-dose regimen of Clostridium difficile vaccine.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Clostridium difficile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,994 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2020-12-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03918629
The ClinicalTrials.gov registry entry for NCT03918629 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,994 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03918629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03918629 about?
NCT03918629 is a clinical study titled "Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study". This study will investigate a Clostridium difficile vaccine in adults 50 years of age and older. In half the adults, all 3 doses given are the Clostridium difficile vaccine, and in half the adults, 2 of the 3 doses are the Clostridium difficile vaccine with the other dose containing no active ingred...
What is the current status of trial NCT03918629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,994 participants. The study started on 2019-04-01. Estimated completion is 2020-12-22.
What interventions are being tested in trial NCT03918629?
The interventions under investigation include: Placebo (BIOLOGICAL), Clostridium difficile (BIOLOGICAL).
Who is sponsoring clinical trial NCT03918629?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.